P297 The Toronto IBD Global Endoscopic Reporting (TIGER) Score and its Ability to Predict Outcomes Regarding Steroid and Biologic Use in Ulcerative Colitis and Crohn’s Disease Patients – A Construct Validation Study

Abstract Background The recently developed TIGER endoscopy score was established to reliably describe disease severity as it can be utilized for both Ulcerative Colitis (UC) and Crohn’s (CD) patients.1The aim of this prospective study assess the score’s ability predict UC CD patient outcomes including biologic steroid use. Methods A cohort 78 patients with (n=40) (n=38) were included in a 52-week multiple visit study. Each interviews using IBD disk questionnaire, blood draws C-reactive protein (CRP), fecal calprotectin (FC). Endoscopy assessment performed at baseline. Administration steroids, immunomodulators (IMN), biologics, dose escalations recorded. Baseline total scores dichotomized <100 points (remission-mild endoscopic activity) or ≥100 (moderate-severe predictor therapeutic outcomes. Results At baseline, compared <100, had significantly higher CRP (p<0.0005), FC (p<0.0001), (p<0.0001). In patients, (p<0.0006), ( p<0.006), p<0.0001). 52-weeks, baseline increased likelihood requiring steroids therapy Specifically, 7.1% 0% required 73.1% 48.3% ≥100, respectively. Moreover, >100 being prescribed having subsequently escalate More specifically, 11.1% 92.3% 100% Conclusion demonstrates significant association CRP, patients. measure moderate-to-severe burden certain interventions. These data suggest that reflects subsequent need pharmacologic intervention 1. Zittan E, et al. J Crohns 2022;16:544-553.